{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T11:25:43Z","timestamp":1761823543557},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,2,21]],"date-time":"2013-02-21T00:00:00Z","timestamp":1361404800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Heart Vessels"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1007\/s00380-013-0325-2","type":"journal-article","created":{"date-parts":[[2013,2,20]],"date-time":"2013-02-20T11:04:34Z","timestamp":1361358274000},"page":"21-28","source":"Crossref","is-referenced-by-count":27,"title":["Effects of statin treatment in patients with coronary artery disease and chronic kidney disease"],"prefix":"10.1007","volume":"29","author":[{"given":"Hidehiro","family":"Kaneko","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junji","family":"Yajima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Oikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shingo","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Fukamachi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Sagara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Otsuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunsuke","family":"Matsuno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryuichi","family":"Funada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroto","family":"Kano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tokuhisa","family":"Uejima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Koike","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuyuki","family":"Nagashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hajime","family":"Kirigaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Sawada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadanori","family":"Aizawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,2,21]]},"reference":[{"key":"325_CR1","doi-asserted-by":"crossref","first-page":"137","DOI":"10.7326\/0003-4819-139-2-200307150-00013","volume":"139","author":"AS Levey","year":"2003","unstructured":"Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, Hogg RJ, Perrone RD, Lau J, Eknoyan G (2003) National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 139:137\u2013147","journal-title":"Ann Intern Med"},{"key":"325_CR2","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1161\/01.CIR.0000095676.90936.80","volume":"108","author":"MJ Sarnak","year":"2003","unstructured":"Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, Wilson PW (2003) Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 108:2154\u20132169","journal-title":"Circulation"},{"key":"325_CR3","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1136\/bmj.38814.566019.2F","volume":"332","author":"M Tonelli","year":"2006","unstructured":"Tonelli M, Jose P, Curhan G, Sacks F, Braunwald E, Pfeffer M (2006) Proteinuria, impaired kidney function, and adverse outcomes in people with coronary disease: analysis of a previously conducted randomised trial. BMJ 332:1426","journal-title":"BMJ"},{"key":"325_CR4","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/S0002-9149(03)00147-4","volume":"91","author":"S Wison","year":"2003","unstructured":"Wison S, Foo K, Cunningham J, Cooper J, Deaner A, Knight C, Ranjadayalan K, Timmis AD (2003) Renal function and risk stratification in acute coronary syndromes. Am J Cardiol 91:1051\u20131054","journal-title":"Am J Cardiol"},{"key":"325_CR5","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1046\/j.1523-1755.2003.00784.x","volume":"63","author":"H Reinecke","year":"2003","unstructured":"Reinecke H, Trey T, Matzkies F, Fobker M, Breithardt G, Schaefer RM (2003) Grade of chronic renal failure, and acute and long-term outcome after percutaneous coronary interventions. Kidney Int 63:696\u2013701","journal-title":"Kidney Int"},{"key":"325_CR6","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJM199511163332001","volume":"333","author":"J Shepherd","year":"1995","unstructured":"Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ (1995) Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 333:1301\u20131307","journal-title":"N Engl J Med"},{"key":"325_CR7","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","volume":"359","author":"PM Ridker","year":"2008","unstructured":"Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ (2008) Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359:2195\u20132207","journal-title":"N Engl J Med"},{"key":"325_CR8","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1016\/j.jacc.2008.08.039","volume":"52","author":"EJ Mills","year":"2008","unstructured":"Mills EJ, Rachlis B, Wu P, Devereaux PJ, Arora P, Perri D (2008) Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients. J Am Coll Cardiol 52:1769\u20131781","journal-title":"J Am Coll Cardiol"},{"key":"325_CR9","unstructured":"(1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344:1383\u20131389"},{"key":"325_CR10","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJM199610033351401","volume":"335","author":"FM Sacks","year":"1996","unstructured":"Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E (1996) The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 335:1001\u20131009","journal-title":"N Engl J Med"},{"key":"325_CR11","doi-asserted-by":"crossref","unstructured":"(1998) Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 339:1349\u20131357","DOI":"10.1056\/NEJM199811053391902"},{"key":"325_CR12","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1001\/jama.285.4.430","volume":"285","author":"U Stenestrand","year":"2001","unstructured":"Stenestrand U, Wallentin L (2001) Early statin treatment following acute myocardial infarction and 1-year survival. JAMA 285:430\u2013436","journal-title":"JAMA"},{"key":"325_CR13","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/S0140-6736(00)04257-4","volume":"357","author":"HD Aronow","year":"2001","unstructured":"Aronow HD, Topol EJ, Roe MT, Houghtaling PL, Wolski KE, Lincoff AM, Harrington RA, Califf RM, Ohman EM, Kleiman NS, Keltai M, Wilcox RG, Vahanian A, Armstrong PW, Lauer MS (2001) Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study. Lancet 357:1063\u20131068","journal-title":"Lancet"},{"key":"325_CR14","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/j.jacc.2007.11.072","volume":"51","author":"J Shepherd","year":"2008","unstructured":"Shepherd J, Kastelein JJ, Bittner V, Deedwania P, Breazna A, Dobson S, Wilson DJ, Zuckerman A, Wenger NK (2008) Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. J Am Coll Cardiol 51:1448\u20131454","journal-title":"J Am Coll Cardiol"},{"key":"325_CR15","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/j.jacc.2010.01.020","volume":"55","author":"PM Ridker","year":"2010","unstructured":"Ridker PM, MacFadyen J, Cressman M, Glynn RJ (2010) Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention\u2014an Intervention Trial Evaluating Rosuvastatin) trial. J Am Coll Cardiol 55:1266\u20131273","journal-title":"J Am Coll Cardiol"},{"key":"325_CR16","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1161\/01.STR.0000090348.52943.A2","volume":"34","author":"M Kubo","year":"2003","unstructured":"Kubo M, Kiyohara Y, Kato I, Tanizaki Y, Arima H, Tanaka K, Nakamura H, Okubo K, Iida M (2003) Trends in the incidence, mortality, and survival rate of cardiovascular disease in a Japanese community: the Hisayama study. Stroke 34:2349\u20132354","journal-title":"Stroke"},{"key":"325_CR17","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/hr.2009.114","volume":"32","author":"M Nakamura","year":"2009","unstructured":"Nakamura M, Yamashita T, Yajima J, Oikawa Y, Ogasawara K, Kirigaya H, Sagara K, Koike A, Sawada H, Aizawa T (2009) Impact of reduced renal function on prognosis in Japanese patients with coronary artery disease: a prospective cohort of Shinken Database 2007. Hypertens Res 32:920\u2013926","journal-title":"Hypertens Res"},{"key":"325_CR18","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.amjcard.2005.11.031","volume":"97","author":"T Sakamoto","year":"2006","unstructured":"Sakamoto T, Kojima S, Ogawa H, Shimomura H, Kimura K, Ogata Y, Sakaino N, Kitagawa A (2006) Effects of early statin treatment on symptomatic heart failure and ischemic events after acute myocardial infarction in Japanese. Am J Cardiol 97:1165\u20131171","journal-title":"Am J Cardiol"},{"key":"325_CR19","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","volume":"350","author":"CP Cannon","year":"2004","unstructured":"Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM (2004) Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350:1495\u20131504","journal-title":"N Engl J Med"},{"key":"325_CR20","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.amjcard.2007.04.053","volume":"100","author":"SA Murphy","year":"2007","unstructured":"Murphy SA, Cannon CP, Wiviott SD, de Lemos JA, Blazing MA, McCabe CH, Califf RM, Braunwald E (2007) Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trials). Am J Cardiol 100:1047\u20131051","journal-title":"Am J Cardiol"},{"key":"325_CR21","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa050461","volume":"352","author":"JC LaRosa","year":"2005","unstructured":"LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK (2005) Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352:1425\u20131435","journal-title":"N Engl J Med"},{"key":"325_CR22","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.amjcard.2006.08.051","volume":"99","author":"JK Liao","year":"2007","unstructured":"Liao JK (2007) Safety and efficacy of statins in Asians. Am J Cardiol 99:410\u2013414","journal-title":"Am J Cardiol"},{"key":"325_CR23","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jjcc.2010.11.004","volume":"57","author":"M Nakamura","year":"2011","unstructured":"Nakamura M, Yamashita T, Yajima J, Oikawa Y, Ogasawara K, Sagara K, Koike A, Kirigaya H, Nagashima K, Otsuka T, Uejima T, Funada R, Matsuno S, Suzuki S, Sawada H, Aizawa T (2011) Impact of early statin initiation on secondary prevention in Japanese patients with coronary artery disease. J Cardiol 57:172\u2013180","journal-title":"J Cardiol"},{"key":"325_CR24","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1253\/circj.72.914","volume":"72","author":"S Suzuki","year":"2008","unstructured":"Suzuki S, Yamashita T, Ohtsuka T, Sagara K, Uejima T, Oikawa Y, Yajima J, Koike A, Nagashima K, Kirigaya H, Ogasawara K, Sawada H, Aizawa T (2008) Prevalence and prognosis of patients with atrial fibrillation in Japan: a prospective cohort of Shinken Database 2004. Circ J 72:914\u2013920","journal-title":"Circ J"},{"key":"325_CR25","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","volume":"53","author":"S Matsuo","year":"2009","unstructured":"Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A (2009) Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 53:982\u2013992","journal-title":"Am J Kidney Dis"},{"key":"325_CR26","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1001\/jama.2011.601","volume":"305","author":"WB Borden","year":"2011","unstructured":"Borden WB, Redberg RF, Mushlin AI, Dai D, Kaltenbach LA, Spertus JA (2011) Patterns and intensity of medical therapy in patients undergoing percutaneous coronary intervention. JAMA 305:1882\u20131889","journal-title":"JAMA"},{"key":"325_CR27","doi-asserted-by":"crossref","first-page":"82C","DOI":"10.1016\/j.amjcard.2005.12.015","volume":"97","author":"BL Kasiske","year":"2006","unstructured":"Kasiske BL, Wanner C, O\u2019Neill WC (2006) An assessment of statin safety by nephrologists. Am J Cardiol 97:82C\u201385C","journal-title":"Am J Cardiol"},{"key":"325_CR28","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1046\/j.1523-1755.2002.00109.x","volume":"61","author":"SL Seliger","year":"2002","unstructured":"Seliger SL, Weiss NS, Gillen DL, Kestenbaum B, Ball A, Sherrard DJ, Stehman-Breen CO (2002) HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney Int 61:297\u2013304","journal-title":"Kidney Int"},{"key":"325_CR29","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1053\/ajkd.2002.34927","volume":"40","author":"FG Cosio","year":"2002","unstructured":"Cosio FG, Pesavento TE, Pelletier RP, Henry M, Ferguson RM, Kim S, Lemeshow S (2002) Patient survival after renal transplantation III: the effects of statins. Am J Kidney Dis 40:638\u2013643","journal-title":"Am J Kidney Dis"},{"key":"325_CR30","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1016\/S0140-6736(03)13638-0","volume":"361","author":"H Holdaas","year":"2003","unstructured":"Holdaas H, Fellstrom B, Jardine AG, Holme I, Nyberg G, Fauchald P, Gronhagen-Riska C, Madsen S, Neumayer HH, Cole E, Maes B, Ambuhl P, Olsson AG, Hartmann A, Solbu DO, Pedersen TR (2003) Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 361:2024\u20132031","journal-title":"Lancet"},{"key":"325_CR31","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1161\/01.CIR.0000143892.84582.60","volume":"110","author":"M Tonelli","year":"2004","unstructured":"Tonelli M, Isles C, Curhan GC, Tonkin A, Pfeffer MA, Shepherd J, Sacks FM, Furberg C, Cobbe SM, Simes J, Craven T, West M (2004) Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation 110:1557\u20131563","journal-title":"Circulation"},{"key":"325_CR32","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa043545","volume":"353","author":"C Wanner","year":"2005","unstructured":"Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, Ritz E (2005) Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353:238\u2013248","journal-title":"N Engl J Med"},{"key":"325_CR33","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1161\/01.CIR.99.25.3227","volume":"99","author":"J Dupuis","year":"1999","unstructured":"Dupuis J, Tardif JC, Cernacek P, Theroux P (1999) Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial. Circulation 99:3227\u20133233","journal-title":"Circulation"},{"key":"325_CR34","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1161\/01.CIR.100.3.230","volume":"100","author":"PM Ridker","year":"1999","unstructured":"Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E (1999) Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 100:230\u2013235","journal-title":"Circulation"},{"key":"325_CR35","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/S0140-6736(09)60447-5","volume":"373","author":"PM Ridker","year":"2009","unstructured":"Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, Macfadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ (2009) Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 373:1175\u20131182","journal-title":"Lancet"}],"container-title":["Heart and Vessels"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00380-013-0325-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00380-013-0325-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00380-013-0325-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,26]],"date-time":"2019-02-26T19:13:59Z","timestamp":1551208439000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00380-013-0325-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2,21]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["325"],"URL":"https:\/\/doi.org\/10.1007\/s00380-013-0325-2","relation":{},"ISSN":["0910-8327","1615-2573"],"issn-type":[{"value":"0910-8327","type":"print"},{"value":"1615-2573","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,2,21]]}}}